Preview

Атеротромбоз

Расширенный поиск

«НЕПОТЕРЯННОЕ ВРЕМЯ» В ПРОФИЛАКТИКЕ РАЗВИТИЯ ОСЛОЖНЕНИЙ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ: ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ПРИМЕНЕНИЯ СТАТИНОВ С ЦЕЛЬЮ ПЕРВИЧНОЙ ПРОФИЛАКТИКИ

https://doi.org/10.21518/2307-1109-2016-2-98-105

Полный текст:

Аннотация

В статье рассматриваются современные подходы к определению показаний к назначению статинов с целью первичной профилактики развития осложнений сердечно-сосудистых заболеваний. Обсуждаются результаты недавно выполненных обсервационных исследований по оценке обоснованности разных подходов к назначению статинов у лиц без установленного диагноза сердечно-сосудистых заболеваний, включая использование определенных шкал для оценки риска развития таких заболеваний или критериев включения в рандомизиро- ванные исследования по оценке эффективности применения статинов. Приводятся данные о сравнительной эффективности современных статинов по влиянию на уровень холестерина липопротеинов низкой плотности в крови.

Об авторах

С. Р. Гиляревский
Российская медицинская академия последипломного образования Минздрава России
Россия
д.м.н., профессор


И. М. Кузьмина
НИИ скорой помощи им. Н.В. Склифосовского
Россия
к.м.н.


М. В. Голшмид
Российская медицинская академия последипломного образования Минздрава России
Россия
к.м.н.


Г. Ю. Захарова
Российская медицинская академия последипломного образования Минздрава России
Россия
к.м.н.


Список литературы

1. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation, 2014, 129(25 suppl 2): 1-45.

2. Perk J, De Backer G, Gohlke H et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J, 2012, 33: 1635-1701.

3. The Guidelines Battle on Starting Statins. New Engl J Med, 2014, 370: 1652-1658.

4. Redberg RF, Katz MH. Healthy men should not take statins. JAMA, 2012, 307: 1491-1492.

5. Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular Disease. JAMA, 2013, 310: 2451-2452.

6. Yeboah J, Sillau S, Delaney JC et al. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J, 2015, 169: 387-395.

7. Ford I, Murray H, McCowan C, Packard CJ. Long Term Safety and Efficacy of Lowering LDL Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation, 2016 Feb 10. [Epub ahead of print].

8. Sever PS, Chang CL, Gupta AK et al. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J, 2011, 32: 2525-2532.

9. Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med, 2008, 359: 2195-220.

10. Goff DC, Lloyd-Jones DM, Bennett G et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014, 63: 2935-2959.

11. National Institute for Health and Care Excellence (NICE). Clinical Guideline CG181: lipid modification — cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available at: http://www.nice.org.uk/Guidance/cg181. Accessed July 26, 2014.

12. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart, 2014, 100: ii1-67.

13. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation, 2010, 121: 1768-1777.

14. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol, 2009, 54: 1209-1227.

15. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. J Am Coll Cardiol, 2015, 66: 2699-2709.

16. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet, 2013, 382: 1762-1765.

17. Ridker PM, Wilson PW. A trial-based approach to statin guidelines. JAMA, 2013, 310: 1123-1124.

18. Ridker PM, Rose L, Cook NR. A Proposal to incorporate trial data into a hybrid ACC/AHA al— gorithm for the allocation of statin therapy in primary prevention. J Am Coll Cardiol, 2015, 65: 942-948.

19. Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med, 2014, 174: 15-22.

20. Nordestgaard BG, Palmer TM, Benn M et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med, 2012, 9: e1001212.

21. Jњrgensen AB, Frikke-Schmidt R, Nordestgaard BG et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med, 2014, 371: 32-41.

22. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study. Eur Heart J, 2015, 36: 2446-2453.

23. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333: 1301-1307.

24. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lova— statin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279: 1615- 1622.

25. Sever PS, Dahlo_f B, Poulter NR et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than— average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361: 1149- 1158.

26. Nakamura H, Arakawa K, Itakura H, et al. for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006, 368: 1155-1163.

27. Ridker PM, Danielson E, Fonseca FA et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008, 359: 2195-2207.

28. Colhoun HM, Betteridge DJ, Durrington PN et al. for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364: 685-696.

29. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol, 2003, 92: 152-160.

30. McKenney JM, Jones PH, Adamczyk MA et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin, 2003, 19: 689-698.


Для цитирования:


Гиляревский С.Р., Кузьмина И.М., Голшмид М.В., Захарова Г.Ю. «НЕПОТЕРЯННОЕ ВРЕМЯ» В ПРОФИЛАКТИКЕ РАЗВИТИЯ ОСЛОЖНЕНИЙ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ: ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ПРИМЕНЕНИЯ СТАТИНОВ С ЦЕЛЬЮ ПЕРВИЧНОЙ ПРОФИЛАКТИКИ. Атеротромбоз. 2016;(2):108-116. https://doi.org/10.21518/2307-1109-2016-2-98-105

For citation:


., ., ., . . Atherothrombosis Journal. 2016;(2):108-116. (In Russ.) https://doi.org/10.21518/2307-1109-2016-2-98-105

Просмотров: 183


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)